Literature DB >> 18049895

Path models of quality of life among people with schizophrenia living in the community in Hong Kong.

Sunny Ho Wan Chan1, Frederick Ka Ching Yeung.   

Abstract

The utilization of quality of life (QOL) in psychiatric community rehabilitation could be enhanced by developing an appropriate conceptual model of QOL. The focus of this study was to construct and test, using path analytic techniques, a pertinent conceptual model of QOL among people with schizophrenia living in the community. A total of 201 participants with schizophrenia living in the community were assessed with regard to their clinical characteristics and QOL. Findings largely supported the proposed model in which community/social functioning was the strongest predictor of QOL, followed by symptom levels. Important implications for the design and implementation of appropriate services in functioning augmentation that resulted in QOL enhancement were highlighted. Further recommendations on both clinical and environmental interventions to promote QOL were suggested.

Entities:  

Mesh:

Year:  2007        PMID: 18049895     DOI: 10.1007/s10597-007-9114-7

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  51 in total

1.  The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale.

Authors:  R M Norman; A K Malla; T McLean; L P Voruganti; L Cortese; E McIntosh; S Cheng; A Rickwood
Journal:  Acta Psychiatr Scand       Date:  2000-10       Impact factor: 6.392

2.  Intervention research in psychosis: issues related to the assessment of quality of life.

Authors:  A G Awad; L N Voruganti
Journal:  Schizophr Bull       Date:  2000       Impact factor: 9.306

3.  Relationships between satisfaction with occupational factors and health-related variables in schizophrenia outpatients.

Authors:  M Eklund; L Hansson; U Bejerholm
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2001-02       Impact factor: 4.328

4.  Adolescent performance on the Allen Cognitive Levels Screen.

Authors:  Sloane Nguyen Lee; Audrey Gargiullo; Sara Brayman; Jodi Coppage Kinsey; Hope Carroll Jones; Mary Shotwell
Journal:  Am J Occup Ther       Date:  2003 May-Jun

5.  Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: a prospective open trial.

Authors:  Wai-Kwong Tang; Gabor S Ungvari
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-05       Impact factor: 5.067

6.  From Leros asylum to community-based facilities: levels of functioning and quality of life among hostel residents in Greece.

Authors:  A Zissi; M M Barry
Journal:  Int J Soc Psychiatry       Date:  1997

7.  Health-related quality of life in older patients with schizophrenia and other psychoses: relationships among psychosocial and psychiatric factors.

Authors:  T L Patterson; W Shaw; S J Semple; S Moscona; M J Harris; R M Kaplan; I Grant; D V Jeste
Journal:  Int J Geriatr Psychiatry       Date:  1997-04       Impact factor: 3.485

8.  Can older people with schizophrenia benefit from work rehabilitation?

Authors:  Morris D Bell; Joanna M Fiszdon; Tamasine C Greig; Gary J Bryson
Journal:  J Nerv Ment Dis       Date:  2005-05       Impact factor: 2.254

9.  A community study of the health-related quality of life of schizophrenia and general practice outpatients in Singapore.

Authors:  Hao-Yang Tan; Wei-Chieh Choo; Sanjay Doshi; Leslie E C Lim; Ee-Heok Kua
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2004-02       Impact factor: 4.328

10.  Quality of life benefits of paid work activity in schizophrenia.

Authors:  Gary Bryson; Paul Lysaker; Morris Bell
Journal:  Schizophr Bull       Date:  2002       Impact factor: 9.306

View more
  1 in total

1.  Typology of changes in quality of life over 12 months among currently or formerly homeless individuals using different housing services in Quebec, Canada.

Authors:  Gesthika Kaltsidis; Guy Grenier; Zhirong Cao; Nadia L'Espérance; Marie-Josée Fleury
Journal:  Health Qual Life Outcomes       Date:  2021-04-21       Impact factor: 3.186

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.